|
|
|
910 Clopper Road, Suite 220N Gaithersburg, MD 20878 ph: 240-632-0740 fx: 240-632-0735 www.genvec.com |
| |
| | | |
|
|
|
|
Very truly yours, |
|
|
|
|
|
/s/ Douglas J. Swirsky |
|
|
|
|
|
Douglas J. Swirsky President and Chief Executive Officer |
|
| | | |
|
|
|
|
By Order of the Board of Directors |
|
|
|
|
|
/s/ Douglas J. Swirsky |
|
|
|
|
|
Douglas J. Swirsky President and Chief Executive Officer Gaithersburg, Maryland November 4, 2014 |
|
| | | |
|
Director Nominees |
|
|
Position with Company |
|
---|---|---|---|---|---|
|
Stefan D. Loren, Ph.D. |
|
|
Director |
|
|
Marc R. Schneebaum |
|
|
Director |
|
| | | |
|
Continuing Directors |
|
|
Position(s) with Company |
|
|
Year Current Term Expires |
|
---|---|---|---|---|---|---|---|---|
|
Wayne T. Hockmeyer, Ph.D. |
|
|
Chairman of the Board of Directors |
|
|
2015 |
|
|
Douglas J. Swirsky |
|
|
President, Chief Executive Officer and Director |
|
|
2015 |
|
|
William N. Kelley, M.D. |
|
|
Director |
|
|
2016 |
|
|
Quinterol J. Mallette, M.D. |
|
|
Director |
|
|
2016 |
|
| | | | | |
|
Name |
|
|
Age |
|
|
Position |
|
---|---|---|---|---|---|---|---|---|
|
Directors whose terms expire at the Annual Meeting |
|
|
|
|
|
|
|
|
Stefan D. Loren, Ph.D.(1)(3) |
|
|
50 |
|
|
Director (nominee) |
|
|
Marc R. Schneebaum(1)(2) |
|
|
60 |
|
|
Director (nominee) |
|
|
Continuing Directors whose terms expire in 2015 |
|
|
|
|
|
|
|
|
Wayne T. Hockmeyer, Ph.D.(2)(3) |
|
|
69 |
|
|
Chairman of the Board of Directors |
|
|
Douglas J. Swirsky |
|
|
44 |
|
|
President, Chief Executive Officer and Director |
|
|
Continuing Directors whose terms expire in 2016 |
|
|
|
|
|
|
|
|
William N. Kelley, M.D.(2)(3) |
|
|
75 |
|
|
Director |
|
|
Quinterol J. Mallette, M.D.(1) |
|
|
40 |
|
|
Director |
|
| | | | | |
|
Name(1) |
|
|
Fees Earned or Paid in Cash(2) ($) |
|
|
Restricted StockAwards ($) |
|
|
Option Awards ($) |
|
|
Total ($) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Wayne T. Hockmeyer, Ph.D. |
|
|
|
$ |
88,500 |
|
|
|
|
$ |
19,950 |
(3) |
|
|
|
|
$ |
— |
|
|
|
|
$ |
108,450 |
|
| |||
|
Zola P. Horovitz, Ph.D.(4) |
|
|
|
$ |
101,250 |
|
|
|
|
$ |
19,950 |
(3) |
|
|
|
|
$ |
— |
|
|
|
|
$ |
121,200 |
|
| |||
|
William N. Kelley, M.D. |
|
|
|
$ |
77,500 |
|
|
|
|
$ |
19,950 |
(3) |
|
|
|
|
$ |
— |
|
|
|
|
$ |
97,450 |
|
| |||
|
Marc R. Schneebaum |
|
|
|
$ |
91,500 |
|
|
|
|
$ |
19,950 |
(3) |
|
|
|
|
$ |
— |
|
|
|
|
$ |
111,450 |
|
| |||
|
Stefan D. Loren, Ph.D. |
|
|
|
$ |
10,978 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
32,923 |
(3) |
|
|
|
|
$ |
43,901 |
|
| |||
|
Edward M. Connor, Jr., M.D.(4) |
|
|
|
$ |
44,299 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
— |
|
|
|
|
$ |
44,299 |
|
| ||||
|
Adel A.F. Mahmoud, M.D., Ph.D.(4) |
|
|
|
$ |
40,299 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
— |
|
|
|
|
$ |
40,299 |
|
| ||||
|
Kevin M. Rooney(4) |
|
|
|
$ |
41,299 |
|
|
|
|
$ |
— |
|
|
|
|
$ |
— |
|
|
|
|
$ |
41,299 |
|
| ||||
| | | | | | | | | | | | | | |
|
Name(1) |
|
|
Total (#) |
|
|
Vested (#) |
|
|
Unvested (#) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Wayne T. Hockmeyer, Ph.D. |
|
|
|
|
102,000 |
|
|
|
|
|
27,000 |
|
|
|
|
|
75,000 |
|
| |||
|
Zola P. Horovitz, Ph.D.(2) |
|
|
|
|
114,000 |
|
|
|
|
|
39,000 |
|
|
|
|
|
75,000 |
|
| |||
|
William N. Kelley, M.D. |
|
|
|
|
102,000 |
|
|
|
|
|
27,000 |
|
|
|
|
|
75,000 |
|
| |||
|
Marc R. Schneebaum |
|
|
|
|
99,500 |
|
|
|
|
|
24,500 |
|
|
|
|
|
75,000 |
|
| |||
|
Stefan D. Loren, Ph.D. |
|
|
|
|
35,000 |
|
|
|
|
|
— |
|
|
|
|
|
35,000 |
|
| |||
|
Kevin M. Rooney(2) |
|
|
|
|
23,000 |
|
|
|
|
|
23,000 |
|
|
|
|
|
— |
|
| |||
|
Edward M. Connor, Jr., M.D.(2) |
|
|
|
|
17,500 |
|
|
|
|
|
17,500 |
|
|
|
|
|
— |
|
| |||
|
Adel A.F. Mahmoud, M.D., Ph.D.(2) |
|
|
|
|
17,500 |
|
|
|
|
|
17,500 |
|
|
|
|
|
— |
|
| |||
| | | | | | | | | | | |
|
Name and Principal Position(1) |
|
|
Year |
|
|
Salary ($) |
|
|
Stock Awards ($)(2) |
|
|
Option Awards ($)(2) |
|
|
Non-Equity Incentive Plan Compensation ($)(3) |
|
|
All Other Compensation ($)(4) |
|
|
Total ($) |
| ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Douglas J. Swirsky, Chief Executive Officer |
|
|
|
|
2013 |
|
|
|
|
|
316,259 |
|
|
|
|
|
53,200 |
|
|
|
|
|
152,156 |
|
|
|
|
|
— |
|
|
|
|
|
6,500 |
|
|
|
|
|
528,115 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
|
310,919 |
|
|
|
|
|
— |
|
|
|
|
|
117,138 |
|
|
|
|
|
75,305 |
|
|
|
|
|
10,175 |
|
|
|
|
|
513,537 |
|
| ||||||||||
|
Cynthia Collins, Former Chief Executive Officer |
|
|
|
|
2013 |
|
|
|
|
|
303,750 |
|
|
|
|
|
— |
|
|
|
|
|
257,496 |
|
|
|
|
|
— |
|
|
|
|
|
249,269 |
|
|
|
|
|
810,515 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
|
273,438 |
|
|
|
|
|
— |
|
|
|
|
|
497,404 |
|
|
|
|
|
126,000 |
|
|
|
|
|
59,996 |
|
|
|
|
|
956,838 |
|
| ||||||||||
|
Douglas E. Brough, Chief Scientific Officer |
|
|
|
|
2013 |
|
|
|
|
|
310,650 |
|
|
|
|
|
33,250 |
|
|
|
|
|
103,466 |
|
|
|
|
|
— |
|
|
|
|
|
6,500 |
|
|
|
|
|
453,866 |
|
| |||||||
|
|
|
2012 |
|
|
|
|
|
288,206 |
|
|
|
|
|
— |
|
|
|
|
|
146,423 |
|
|
|
|
|
64,491 |
|
|
|
|
|
8,960 |
|
|
|
|
|
508,080 |
|
| ||||||||||
|
Bryan T. Butman, Senior Vice President, Development(5) |
|
|
|
|
2013 |
|
|
|
|
|
278,060 |
|
|
|
|
|
19,950 |
|
|
|
|
|
91,294 |
|
|
|
|
|
— |
|
|
|
|
|
6,500 |
|
|
|
|
|
395,804 |
|
| |||||||
| | | | | | | | | | | | | | | | | | | | | | | |
|
Hearing Program |
|
|
File IND (weighted 40%) |
|
|
Business Development |
|
|
Enter new corporate collaboration for RSV, HSV, or TNFerade (weighted 25%) |
|
|
Hearing Program |
|
|
Treat first patient (weighted 15%) |
|
|
Malaria Program |
|
|
Manufacture three Bulk Drug Lots (weighted 10%) |
|
|
Financial Goals |
|
|
2013 Cash Burn of $8M or less and other corporate initiatives (weighted 10%) |
|
| | | |
|
|
|
|
Option Awards |
|
|
Stock Awards |
| ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Name |
|
|
Number of Securities Underlying Unexercised Options Exercisable (#) |
|
|
Number of Securities Underlying Unexercised Options Unexercisable (#)(1) |
|
|
Option Exercise Price ($) |
|
|
Option Expiration Date |
|
|
Number of Shares or Units of Stock That Have Not Vested (#)(2) |
|
|
Market Value of Shares or Units of Stock That Have Not Vested ($)(2) |
| ||||||||||||||||||||||||
|
Cynthia Collins |
|
|
|
|
83,333 |
|
|
|
|
|
— |
|
|
|
|
|
2.54 |
|
|
|
|
|
5/23/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
33,333 |
|
|
|
|
|
— |
|
|
|
|
|
1.65 |
|
|
|
|
|
1/23/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
Paul H. Fischer |
|
|
|
|
150,000 |
|
|
|
|
|
— |
|
|
|
|
|
2.49 |
|
|
|
|
|
6/1/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
Douglas J. Swirsky |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000 |
|
|
|
|
|
464,000 |
|
| ||||||
|
|
|
|
|
|
30,000 |
|
|
|
|
|
— |
|
|
|
|
|
11.30 |
|
|
|
|
|
9/18/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
3,000 |
|
|
|
|
|
— |
|
|
|
|
|
26.10 |
|
|
|
|
|
1/18/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
15,000 |
|
|
|
|
|
— |
|
|
|
|
|
17.90 |
|
|
|
|
|
1/16/2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
22,500 |
|
|
|
|
|
— |
|
|
|
|
|
4.10 |
|
|
|
|
|
1/22/2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
14,687 |
|
|
|
|
|
313 |
|
|
|
|
|
22.00 |
|
|
|
|
|
1/20/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
14,583 |
|
|
|
|
|
5,417 |
|
|
|
|
|
5.70 |
|
|
|
|
|
1/19/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
28,750 |
|
|
|
|
|
31,250 |
|
|
|
|
|
2.49 |
|
|
|
|
|
1/18/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
28,645 |
|
|
|
|
|
96,355 |
|
|
|
|
|
1.56 |
|
|
|
|
|
1/22/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
| | | | | | | | | | | | | | | | | | | | |
|
|
|
|
Option Awards |
|
|
Stock Awards |
| ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Name |
|
|
Number of Securities Underlying Unexercised Options Exercisable (#) |
|
|
Number of Securities Underlying Unexercised Options Unexercisable (#)(1) |
|
|
Option Exercise Price ($) |
|
|
Option Expiration Date |
|
|
Number of Shares or Units of Stock That Have Not Vested (#)(2) |
|
|
Market Value of Shares or Units of Stock That Have Not Vested ($)(2) |
| ||||||||||||||||||||||||
|
Douglas E. Brough |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
125,000 |
|
|
|
|
|
290,000 |
|
| ||||||
|
|
|
|
|
|
1,250 |
|
|
|
|
|
— |
|
|
|
|
|
32.10 |
|
|
|
|
|
1/15/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
500 |
|
|
|
|
|
— |
|
|
|
|
|
39.50 |
|
|
|
|
|
3/1/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
2,500 |
|
|
|
|
|
— |
|
|
|
|
|
18.80 |
|
|
|
|
|
1/19/2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
2,500 |
|
|
|
|
|
— |
|
|
|
|
|
16.90 |
|
|
|
|
|
1/18/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
4,000 |
|
|
|
|
|
— |
|
|
|
|
|
26.10 |
|
|
|
|
|
1/18/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
2,500 |
|
|
|
|
|
— |
|
|
|
|
|
17.90 |
|
|
|
|
|
1/16/2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
4,000 |
|
|
|
|
|
— |
|
|
|
|
|
21.80 |
|
|
|
|
|
4/16/2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
4,000 |
|
|
|
|
|
— |
|
|
|
|
|
4.10 |
|
|
|
|
|
1/22/2019 |
|
|
|
|
|
|
|
| | | | | | | | |||||
|
|
|
|
|
|
12,240 |
|
|
|
|
|
260 |
|
|
|
|
|
22.00 |
|
|
|
|
|
1/20/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
3,354 |
|
|
|
|
|
146 |
|
|
|
|
|
17.90 |
|
|
|
|
|
2/1/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
14,583 |
|
|
|
|
|
5,417 |
|
|
|
|
|
5.70 |
|
|
|
|
|
1/19/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
35,937 |
|
|
|
|
|
39,063 |
|
|
|
|
|
2.49 |
|
|
|
|
|
1/18/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
19,479 |
|
|
|
|
|
65,521 |
|
|
|
|
|
1.56 |
|
|
|
|
|
1/22/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
Bryan T. Butman |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,000 |
|
|
|
|
|
174,000 |
|
| ||||||
|
|
|
|
|
|
3,000 |
|
|
|
|
|
— |
|
|
|
|
|
32.10 |
|
|
|
|
|
1/15/2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
4,500 |
|
|
|
|
|
— |
|
|
|
|
|
18.80 |
|
|
|
|
|
1/19/2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
7,500 |
|
|
|
|
|
— |
|
|
|
|
|
16.90 |
|
|
|
|
|
1/18/2016 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
7,500 |
|
|
|
|
|
— |
|
|
|
|
|
26.10 |
|
|
|
|
|
1/18/2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
17,500 |
|
|
|
|
|
— |
|
|
|
|
|
17.90 |
|
|
|
|
|
1/16/2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
22,500 |
|
|
|
|
|
— |
|
|
|
|
|
4.10 |
|
|
|
|
|
1/22/2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
14,687 |
|
|
|
|
|
313 |
|
|
|
|
|
22.00 |
|
|
|
|
|
1/20/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
14,583 |
|
|
|
|
|
5,417 |
|
|
|
|
|
5.70 |
|
|
|
|
|
1/19/2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
28,750 |
|
|
|
|
|
31,250 |
|
|
|
|
|
2.49 |
|
|
|
|
|
1/18/2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
17,187 |
|
|
|
|
|
57,813 |
|
|
|
|
|
1.56 |
|
|
|
|
|
1/22/2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
| | | | | | | | | | | | | | | | | | | | |
|
Fee Category |
|
|
2013 |
|
|
2012 |
| ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Audit Fees |
|
|
|
$ |
250,000 |
|
|
|
|
$ |
328,268 |
|
| ||
|
Audit-Related Fees |
|
|
|
|
— |
|
|
|
|
|
— |
|
| ||
|
Tax Fees |
|
|
|
|
— |
|
|
|
|
|
— |
|
| ||
|
All Other Fees |
|
|
|
|
— |
|
|
|
|
|
— |
|
| ||
|
Total |
|
|
|
$ |
250,000 |
|
|
|
|
$ |
328,268 |
|
| ||
| | | | | | | |
|
Grantee |
|
|
Date of Grant |
|
|
Option Awards (# of Shares Underlying Award) |
|
|
Exercise Price ($) |
|
|
Restricted Stock Awards (# of Shares Underlying Award) |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Paul H. Fisher |
|
|
06/01/2012 |
|
|
150,000 |
|
|
2.49 |
|
|
|
|
|
Cynthia Collins |
|
|
01/23/2013 |
|
|
200,000(1) |
|
|
1.65 |
|
|
|
|
|
Douglas J. Swirsky |
|
|
01/18/2012 |
|
|
60,000 |
|
|
2.49 |
|
|
|
|
|
01/22/2013 |
|
|
125,000 |
|
|
1.56 |
|
|
|
| |||
|
09/03/2013 |
|
|
|
|
|
|
|
|
200,000 |
| |||
|
01/23/2014 |
|
|
75,000 |
|
|
3.96 |
|
|
|
| |||
|
Douglas E. Brough, Ph.D. |
|
|
01/18/2012 |
|
|
75,000 |
|
|
2.49 |
|
|
|
|
|
01/22/2013 |
|
|
85,000 |
|
|
1.56 |
|
|
|
| |||
|
09/03/2013 |
|
|
|
|
|
|
|
|
125,000 |
| |||
|
01/23/2014 |
|
|
50,000 |
|
|
3.96 |
|
|
|
| |||
|
Bryan T. Butman, Ph.D. |
|
|
01/18/2012 |
|
|
60,000 |
|
|
2.49 |
|
|
|
|
|
01/22/2013 |
|
|
75,000 |
|
|
1.56 |
|
|
|
| |||
|
09/03/2013 |
|
|
|
|
|
|
|
|
75,000 |
| |||
|
01/23/2014 |
|
|
40,000 |
|
|
3.96 |
|
|
|
| |||
|
William N. Kelley, Ph.D. |
|
|
09/03/2013 |
|
|
|
|
|
|
|
|
75,000 |
|
|
Marc R. Schneebaum |
|
|
09/03/2013 |
|
|
|
|
|
|
|
|
75,000 |
|
|
Wayne T. Hockmeyer, Ph.D. |
|
|
09/03/2013 |
|
|
|
|
|
|
|
|
75,000 |
|
|
Zola P. Horovitz, Ph.D. |
|
|
09/03/2013 |
|
|
|
|
|
|
|
|
75,000 |
|
|
Stefan D. Loren, Ph.D. |
|
|
09/19/2013 |
|
|
20,000 |
|
|
0.84 |
|
|
|
|
|
11/22/2013 |
|
|
15,000 |
|
|
1.63 |
|
|
|
| |||
|
Non-Executive Employee |
|
|
09/19/2013 |
|
|
|
|
|
|
|
|
15,000 |
|
|
|
|
|
|
|
|
Total: 1,030,000 |
|
|
|
|
|
Total: 715,000 |
|
| | | | | | | | | |
|
Plan category |
|
|
(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights |
|
|
(b) Weighted-average exercise price of outstanding options, warrants and rights |
|
|
(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Equity compensation plans approved by security holders |
|
|
|
|
2,477,081 |
|
|
|
|
$ |
10.03 |
|
|
|
|
|
1,035,125 |
|
| |||
|
Equity compensation plans not approved by security holders |
|
|
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
— |
|
| |||
|
Total |
|
|
|
|
2,477,081 |
|
|
|
|
$ |
10.03 |
|
|
|
|
|
1,035,125 |
|
| |||
| | | | | | | | | | | |
|
Name of Beneficial Owner(1) |
|
|
Total Number of Shares Beneficially Owned |
|
|
% of Class Owned |
| ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Beneficial Owner of More than 5% of the Outstanding Common Stock: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
EcoR1 Capital Fund, L.P. and affiliates(2) |
|
|
|
|
1,840,000 |
|
|
|
|
|
10.65 |
% |
|
| |
|
Cormorant Global Healthcare Master Fund, LP(3) |
|
|
|
|
1,329,300 |
|
|
|
|
|
7.70 |
% |
|
| |
|
Directors and Named Executive Officers: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
Cynthia Collins(4) |
|
|
|
|
116,666 |
|
|
|
|
|
* |
|
| ||
|
Wayne T. Hockmeyer, Ph.D. |
|
|
|
|
103,500 |
|
|
|
|
|
* |
|
| ||
|
William N. Kelley, Ph.D. |
|
|
|
|
101,000 |
|
|
|
|
|
* |
|
| ||
|
Stefan D. Loren, Ph.D. |
|
|
|
|
20,000 |
|
|
|
|
|
* |
|
| ||
|
Marc R. Schneebaum |
|
|
|
|
100,000 |
|
|
|
|
|
* |
|
| ||
|
Quinterol J. Mallette, M.D. |
|
|
|
|
0 |
|
|
|
|
|
* |
|
| ||
|
Douglas J. Swirsky |
|
|
|
|
457,916 |
|
|
|
|
|
2.62 |
% |
|
| |
|
Douglas E. Brough, Ph.D. |
|
|
|
|
294,040 |
|
|
|
|
|
1.69 |
% |
|
| |
|
Bryan T. Butman, Ph.D. |
|
|
|
|
264,321 |
|
|
|
|
|
1.51 |
% |
|
| |
|
All directors and executive officers as a group (8 persons) |
|
|
|
|
1,340,777 |
|
|
|
|
|
7.48 |
% |
|
| |
| | | | | | | | |
|
|
|
|
By Order of the Board of Directors |
|
|
|
|
|
/s/ Douglas J. Swirsky |
|
|
|
|
|
Douglas J. Swirsky President and Chief Executive Officer |
|
| | | |
|
GEORG GARNITSCHNIG, derivatively on behalf of GENVEC, INC. and individually on behalf of himself and all other similarly situated shareholders of GENVEC, INC., Plaintiff, vs. DOUGLAS J. SWIRSKY, CYNTHIA COLLINS, PAUL H. FISCHER, MARC R. SCHNEEBAUM, WAYNE T. HOCKMEYER, WILLIAM N. KELLEY, ZOLA P. HOROVITZ, STEFAN F. LOREN, EDWARD . CONNOR, JR., ADEL A.F. MAHMOUD, KEVIN M. ROONEY, DOUGLAS E. BROUGH, BRYAN T. BUTMAN Defendants, -and- GENVEC, INC., a Delaware Corporation, Nominal Defendant. |
|
|
) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) |
|
|
Civil Action No. 12-cv-00774 AMENDED VERIFIED SHAREHOLDER DERIVATIVEAND CLASS ACTION COMPLAINT DEMAND FOR JURY TRIAL |
|
| | | | | |
|
Dated: November 1, 2013 |
|
|
Respectfully submitted, |
|
|
|
|
|
|
|
|
|
|
|
LEVI & KORSINSKY, LLP |
|
|
|
|
|
|
|
|
|
|
|
/s/ Nicholas I. Porritt |
|
|
|
|
|
|
|
|
|
|
|
Nicholas I. Porritt 1101 30th Street NW, Suite 115 Washington, DC 20007 Telephone: (202) 524-4290 Facsimile: (202) 333-2121 |
|
|
|
|
|
|
|
|
|
|
|
Douglas E. Julie (not admitted to practice in Dist. of MD) 30 Broad Street, 24th Floor New York, NY 10004 Telephone: (212) 363-7500 Facsimile: (866) 367-6510 |
|
|
|
|
|
|
|
|
|
|
|
Attorneys for Plaintiff |
|
| | | |
|
|
|
|
Page |
| ||||
---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
| | | | | |
|
|
|
|
Page |
| ||||
---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
| | | | | |
|
|
|
|
Page |
| ||||
---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| |||
| | | | | |
|
FOR |
|
|
AGAINST |
|
|
ABSTAIN |
|
|
☐ |
|
|
☐ |
|
|
☐ |
|
| | | | | |
|
☐
|
|
|
☐
|
|
|
☐
|
|
| | | | | |
|
FOR |
|
|
AGAINST |
|
|
ABSTAIN |
|
|
☐ |
|
|
☐ |
|
|
☐ |
|
| | | | | |
|
FOR |
|
|
AGAINST |
|
|
ABSTAIN |
|
|
☐ |
|
|
☐ |
|
|
☐ |
|
| | | | | |
|
FOR |
|
|
AGAINST |
|
|
ABSTAIN |
|
|
☐ |
|
|
☐ |
|
|
☐ |
|
| | | | | |
|
FOR |
|
|
AGAINST |
|
|
ABSTAIN |
|
|
☐ |
|
|
☐ |
|
|
☐ |
|
| | | | | |
|
Signature 1 — Please keep signature within the box |
|
|
Signature 2 — Please keep signature within the box |
|
|
Date (mm/dd/yyyy) |
|
|
|
|
|
|
|
|
|
|
| | | | | |
G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`U
M+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@("`@("`@
M("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO 'V]69=1_P`N
MG=>6AI=P]S[DH>MMO^%:V:GR%70T _?;PZW2M?EU__
MTM[3=>VL;N_;F9VMD*:.JBRE!D*`_LYAODT;-M$%L"/(D']A3RZ'6Q?=&Y
DQL^)I]X8V>MI:":AR6.41G(5M)"_P!OED%<@=*,-ZO]
M5Q<6][\O+KW1CQ>PU`!K"X'(!_-C_3WKK?7?OW7NO>_=>ZXN6"DJ`2.;$D7_
M`-L#[]U[J,TET,:2$3O^G]-U/UL`1:PL?J/>Z4H:8ZUTW5>4I2RU^=R=#B
MZ*EC
M]43?S=E;_P!@M4ULS;.W?G-NTTM152@U%/BZV2DAGJ&@F6G5Y!&2
M=/IOP/;F<'32G52!YC/6VG_PE9_EL]*?*#?O9_>?>^TH]ZT/7']V8=J8C(U5
M1+CU.Y,+E
/GN&3EOEN8B-
MT?Q6`(HQU(!^$_"WSZM1HZ*&BBCIJ6..''0QI%34T*>.*&./TI''&MD554`#
M@``>^A]O;V\<$%G9P+':Q@#``X#Y?YNL(V,OBS3SREYF))J2<^M3Z^?3G`7,
M2&1=#\ZEXX]1M]"1]/:TJB$K&>SIM&=E!<4;K+[UU;KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXL2!PI8_T!`_WDD#W[KW7$AF,;7*:>66
M_P!;K;2;&QL??NO==JI#.2Q(8@@$\+Q:P'X]^Z]UXA]0(90OY!4DGZ_0ZA;W
M[KW73QA_[3I_70Y2_%KFWY'OPQU[KDBZ%"ZF:WY=BS'_`%R??NO=